<DOC>
	<DOCNO>NCT00693719</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan etoposide , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give irinotecan together etoposide work treat patient recurrent , locally advanced , metastatic breast cancer .</brief_summary>
	<brief_title>Irinotecan Etoposide Treating Patients With Recurrent , Locally Advanced , Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine response rate , assess RECIST criterion , patient recurrent locally advanced metastatic breast cancer treat irinotecan hydrochloride etoposide prior exposure anthracycline , taxane , capecitabine therapy . Secondary - To determine median time progression patient . - To determine response duration survival patient . - To measure type rate grade 3 great toxicity treatment regimen patient . OUTLINE : Patients receive irinotecan hydrochloride IV day 1 15 oral etoposide day 1-14 . Courses repeat every 28 day absence disease progression unaccepted toxicity . After completion study therapy , patient follow every 3 month 3 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis locally advance metastatic breast cancer Recurrent , refractory progressive disease receive prior anthracycline , taxane , capecitabine therapy Prior anthracycline taxane therapy may neoadjuvant , adjuvant therapy disease progression document within year complete agent Received prior capecitabine therapy metastatic recurrent disease Measurable disease Bone metastases require disease present measure No brain metastasis , unless document controlled postcompletion local therapy ( surgery and/or radiation therapy ) least 4 week No meningeal carcinomatosis No malignant effusion site disease recurrence Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify Performance status 02 Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 40 mL/min Hemoglobin ≥ 10 g/dL ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin normal hyperbilirubinemia &lt; grade 1 ( unless due Gilbert syndrome elevate total normal level conjugate bilirubin ) Not pregnant nursing Fertile patient must use effective contraception No nonbreast malignancy , except nonmelanoma skin cancer No serious underlie medical condition , opinion treat physician , would make study protocol unreasonably hazardous patient would preclude patient 's ability comply study protocol PRIOR CONCURRENT THERAPY : See Disease Characteristic Recovered prior chemotherapy radiotherapy NCI CTC grade ≤ 1 Unlimited document prior chemotherapy regimen allow No prior irinotecan hydrochloride etoposide No Hypericum perforatum ( St. John 's wort ) 14 day prior , , 7 day completion study therapy At least 7 day since prior concurrent phenytoin , carbamazepine , phenobarbital , enzymeinducing anticonvulsant drug ( EIACD ) No concurrent aprepitant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>